Projects

Impact of a vaginal microbiota metabolite on epithelium integrity and HIV susceptibility

Globally, 48% of the 1.8 million new HIV infections in 2016 were among women where the virus mainly establishes infection by entry through the lower female reproductive tract (FRT). In Eastern and South Africa young women (aged 15-24 years) accounted for 26% of new HIV infections in 2016.

Studies have shown that women colonised with non-optimal cervicovaginal microbiota (such as women with bacterial vaginosis, BV) are at increased risk of acquiring HIV compared to women colonised with optimal cervicovaginal microbiota, typically dominated by Lactobacillus spp.

In this study we are investigating how a factor produced by optimal microbiota augments the cervicovaginal mucosal barrier to prevent HIV acquisition

Timeline

2019 – 2021

Publications

2019

Collaborators

Dr Anna Hearps Professor Jacques Ravel Professor Deborah Anderson Professor Adam Burgener Dr Joshua Hayward Associate Professor Catriona Bradshaw Dr Raffi Gugasyan Dr Pantelis Poumbourios

Funding

NHMRC

Contact Details

For any general enquiries relating to this project, please contact:

Professor Gilda Tachedjian

Head of Life Sciences; Head of Tachedjian Laboratory (Retroviral Biology and Antivirals)

Telephone

+61392822256

Email

[email protected]